Osteolytic Bone Metastases Of Solid Tumors

Osteolytic Bone Metastases Of Solid Tumors – General Information

Osteolytic Bone Metastases Of Solid Tumors – Symptoms

The most frequent symptoms developed by the people who suffer from Osteolytic Bone Metastases Of Solid Tumors are high-fever, bone pain, myalgia and others minor flu-like reactions. These appear in about a half of the patients and they usually happen in the first weeks after the disease settles in the body. These reactions normally disappear after a few days, when more critical symptoms come out. Other patients may suffer from anemia or exaggerated fatigue. These particular symptoms have a great influence on the patient’s life and future developments. They cause a lack of concentration, practical skills, attention and they lead to a total change in what concerns the social activities and the interaction with the others. Another less usual but possible symptom of Osteolytic Bone Metastases Of Solid Tumors is a reduction of the renal functions. In this situation, your personal doctor should measure the parameters routinely as this can give you a lot of information about your condition. In addition, this can offer you benefic things, like: measurement of renal function, measurement and identification of the level of impairment, follow-up monitoring, and prescription of drugs. If the tests show that the level of serum creatinine is over the normal standards, then the doctor should confirm this symptom and he should research for reversible effects. Furthermore, if the tests also notice the presence of nephritic or nephrotic syndrome, which leads to the progressive renal changes, than the patient must follow a glomerular filtration procedure, which is absolutely necessarily in such a case.

Osteolytic Bone Metastases Of Solid Tumors – Treatment

The therapies used nowadays in order to treat the patients who suffer from Osteolytic Bone Metastases of Solid Tumors consist of : chemotherapy, radiations, orthopedic surgery, hormone therapy and bisphosphonates therapy. The last one is extremely important as studies showed that if the correct doses are given then the possibility of developing complications of the osseous system almost disappears. On the other hand, another bisphosphonate, pamidronate, is being used world-wide; only 100 mg of this substance every 4 weeks have the power to delay and even reduce the appearance of skeletal problems. In addition, all bisphosphonates are known to have analgesic significations in what concerns bone pain. Recently, the researchers discovered a new substance which can be used in order to treat Osteolytic Bone Metastases Of Solid Tumors, especially if the tumors are located in the lung, prostate or RCC; this is called zoledronic acid.

This is the first substance which proved to significantly reduce the osseous system complications, especially those that develop in the prostate and lungs. The tests performed in order to establish the effectiveness of this drug showed that a 17-minutes infusion with about 5 mg, once in a month, can reduce the frequency of osseous system problems. Moreover, this drug can make the patient live longer as it reduces the skeletal morbidity. During the past years, the role of bisphosphonates in the process of treating the patients diagnosed with Osteolytic Bone Metastases Of Solid Tumors has become more and more important. According to most of the doctors, all sufferers who also develop multiple myeloma, osteopenia or other osteolytic bone complications should use bisphosphonates therapy. Once you have started this kind of treatment you must follow it without interruption, as long as your body accepts it. In addition, those who suffer from Osteolytic Bone Metastases Of Solid Tumors should proceed radiography periodically in order to carefully supervise the evolution of their disease. Another benefic thing about zoledronic acid is the fact that it increases the mineral density of the bones and, in this way, it is efficient even before the appearance of the disease. The correct administration of the doses prescribed by the doctor is vital for reducing the severity and the incidence of the side effects. The most common dosage consists of a 15 minutes infusion with 5 mg of zoledronic acid, once in a month time. It is neither recommended a higher dose nor a smaller one as this can affect the patient’s condition. On contrast, when taking bisphosphonates, you should periodically measure the level of creatinine and iron.  It is also important to be aware of the fact that the administration of zoledronic acid must be stopped at some point. Usually, the patient is suggested to take this drug as long as his body permits or until he notices a significant change of his medical problems. Those who suffer from Osteolytic Bone Metastases Of Solid Tumors should know that it is better to start taking drugs only after the disease was diagnosed, as there was not noticed any important improvement if taking drugs before you consult a specialist.